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ABSTRACT 
 
Pre-eclampsia is a serious pathological state affecting 5-10% of pregnant women. Currently, it is diagnosed in the 
second half of pregnancy, particularly after the 20th week. Symptoms mostly correspond to the changes of blood 
vessels and kidneys. The severity of pre-eclampsia is proportional to symptomatic manifestations, thus the more 
symptoms present, the higher is of pre-eclampsia development. Although there are several studies dealing with pre-
eclampsia pathology, the complete etiology is still unknown. In this review paper, several theories are presented and 
discussed. 
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INTRODUCTION 
 
Pre-eclampsia (PE) is a disorder affecting both the 
mother and the unborn child. It occurs only during 
the pregnancy and may persist until the postpartum 
period. Depending on the nature of the disease, it 
may be distinguished into the mild and severe 
form. In some cases, early and late type of PE is 
indicated and they are discussed as separate 
entities. Mild PE is defined by hypertension 
(≥140/90 mmHg) on two occasions (at least 6 h 
apart) without the evidence of end-organ damage, 
and the presence of 300 mg of proteins in a 24 h 
collected urine sample but no other symptoms 
affecting either mother or baby. Severe PE is 
characterized by blood pressure over 160/110 
mmHg and may lead to liver/renal failure, 
disseminated intravascular coagulopathy and 
central nervous system abnormalities. If PE-
associated seizures are experienced, the disorder 
develops into eclampsia. Premature births, induced 
by PE, are the major cause of maternal, neonatal 
morbidity and the increased mortality of 
newborns. The incidence rate varies from 5 to 8% 
of all the pregnancies in developed European 
countries (Arbogast and Taylor 1996; Pre-
eclampsia foundation 2013).  
Eclampsia and HELLP syndrome (hemolysis, 
elevated liver enzymes, low platelet count) may be 
an outcome of PE. This complex pathological 
condition is most often characterized by the rise in 
blood pressure, which can result in seizures, 
cerebral stroke, multiple organ failure and death of 
the mother and/or child. Swelling, sudden weight 
gain, headache and visual disturbance are less 
frequent symptoms. PE occurs after the 20th week 
of pregnancy and is therefore not diagnosed until 
the second half of pregnancy based on emerging 
clinical symptoms. In rare cases, it may occur 
before the 20th week. Although the etiology is 
unclear, several PE risk factors are known. The 
most common manifestations include 
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hypertension, edema and proteinuria. However, 
the higher permeability of placenta is also 
associated with PE. The higher permeability of 
reactive oxygen species (ROS) through the 
placenta may lead to the development of oxidative 
stress (OS) (Arnostova et al. 2007; Escudero and 
Sobrevia 2008; Pre-eclampsia foundation 2013).  
Several theories have been suggested to explain 
the origin of PE, including the hypothesis of 
uteroplacental ischemia (changes in the biology of 
placenta), immune disorders (systemic 
inflammatory response), genetic predispositions, 
malfunction structures of protein/lipoprotein 
disorders, and the hypothesis of oxygen radicals 
(Anthony and Johanson 1996). The hypothesis of 
uteroplacental ischemia is based on the expression 
of cytotrophoblastic adhesive molecules. It is 
suggested that the reduced penetration of 
substances through placenta leads to fetal damage 
and the release of toxic substances with some 
regulatory factors. A common pathological finding 
is a placenta with multiple surface infarcts 
(Mechurova 2002).  
The current theory concerning the 
pathophysiology of PE relates a lack of trophoblast 
invasion into the wall of the spiral arteries. It is 
linked to the hypothesis of systemic inflammatory 
response supported by the fact that the 
fetoplacental unit contains paternal antigens that 
are capable of slowing down the trophoblast 
invasion. The hepatic expression of human 
leucocyte antigen G (HLA-G) may inhibit 
trophoblast invasion in uterine smooth muscle. 
Subsequently, the activated leukocytes release an 
elastase and attack an endothelium (Mechurova 
2002; Stara 2012). Genetic hypothesis is based on 
the genetic predisposition of daughters whose 
mothers have a verifiable PE history. In this case, 
the risk of disease increases up to 22%, for sisters 
up to 39% (Mechurova 2002). The PE patients 
have a higher concentration of triglyceride and the 
lipoproteins of very low density (VLDL) in the 
plasma. VLDL hypothesis derives from the 
endothelial lining of the vascular damage effect of 
VLDL. The most discussed theory is that of OS. 
The balance between the oxygen radicals and 
antioxidants is disrupted during PE development. 
Natural antioxidant ability is reduced, which may 
lead to placental OS. This hypothesis is supported 
by the fact that the placenta in PE patients exhibits 
discontinuous perfusion due to the reduced 
pathological trophoblast invasion into the maternal 
vascular system. The above mentioned OS is 
considered as a significant consequence causing 
the reduced placental permeability (Borzychowski 
et al. 2006). 
 
 
PATHOLOGY OF PRE-ECLAMPSIA 
 
Nowadays, the PE syndrome is considered as a 
two-stage disease. The first stage is defined by the 
reduced placental permeability (specific proteins, 
placental ‘debris’) associated with abnormal 
implantation and fetal placental release into the 
maternal circulation. The malfunction of placenta 
may, in some cases, induce hypertension, renal 
impairment, proteinuria, damage of other organs 
and HELLP syndrome. The second stage is the 
maternal reaction to this condition. It is 
characterized by inflammation and endothelial 
dysfunction of parental cells (Redman and Sargent 
2000). One of the fundamental pathophysiological 
changes is the so-called firm connection of fetal 
and maternal placenta. Pathological examination 
of placentas has shown placental infarction, 
narrowing of arteries and blood vessels, fibrin 
deposition and venous thrombosis. Placental 
ischemia induces hypertension, proteinuria, which 
is also associated with the deposition of fibrous 
material in the glomerular tubules, called 
glomerular endoteliosis (Baumwell and 
Karumanchi 2007).  
Recent studies deal with the proteins that are 
produced by placenta and inhibit angiogenesis. 
Vascular endothelial growth factor (VEGF) and 
placental growth factor (PIGF) are pro-angiogenic 
factors that are involved in trophoblast 
proliferation (Grill et al. 2009). The growth factors 
and their receptors originate in the placenta. 
Placental cells also secrete the soluble isoform 
receptor (sFlt-1), which is generated through an 
alternative mRNA splicing. Soluble Flt-1 isoform 
has a role as an anti-angiogenic factor. It 
neutralizes the effect of PIGF and VEFG. The 
over-expression of sFlt-1 is associated with 
placental ischemia and hypoxia (Clark et al. 1998). 
Cooper et al. (1996) reported that VEGF and PIGF 
concentration were lower in the second trimester 
in women with late PE in comparison with the 
physiological pregnancies. This fact is most 
significant in the patients with severe PE, where 
VEGF and PIGF amount is reduced in comparison 
with the women with mild PE (St-Jacques et al. 
1994).  
Factors in Pre-eclampsia 
 
Braz. Arch. Biol. Technol. v.57 n.5: pp. 701-705, Sept/Oct 2014 
703 
Maternal immune disorders play an important role 
in the pathophysiology of PE. Trophoblasts 
contain a wide range of immunogenic agents, such 
as HLA-G. This glycoprotein is responsible for the 
low trophoblast immunogenicity along with the 
high resistance to the maternal immune reaction. 
The presence of trophoblast with an insufficient 
HLA-G expression can activate the incompatible 
decidual immune cells in the uterine cavity 
(Matthiesen et al. 2005). The placental vascular 
wall is an integrated organ, composed of 
endothelial cells, smooth muscles and fibroblasts. 
Endothelial cells contain the surface receptors for 
thrombin, clotting factors, angiotensin II, and 
many more. Cytokines (e.g. interferon-gamma) 
and various types of ROS mediate an endothelial 
dysfunction. Clinical symptoms usually appear 
after the 20th week of pregnancy. Endothelial 
dysfunction may result in the increased 
permeability of endothelial cells, activation of 
platelets and the coagulation cascade, shifting the 
balance of vasoactive mediators, and thus favoring 
vasoconstriction and the development of OS 
(Davidge 1998). 
 
 
CLINICAL MANIFESTATION OF PRE-
ECLAMPSIA 
 
The clinical manifestation varies since PE is 
associated with several risk factors (obesity, molar 
pregnancy, hypercoagulation, formation of clots, 
diabetes mellitus). The prevalence of PE increases 
up to 66% if there is already an existing chronic 
kidney disease (Baumwell and Karumanchi 2007). 
It was found that male seminal plasma antigens, 
expressed on trophoblasts, reduce the risk of PE. 
The major clinical manifestation includes 
hypertension, proteinuria, edema, hyperuricemia 
and HELLP syndrome. Blood pressure is a 
function of peripheral vascular resistance and 
cardiac output. According to the World Health 
Organization (WHO), hypertension is considered 
as a blood pressure of 140/90 mmHg or higher at 
two separate measurements within 6 h (Hajek 
1999). Proteinuria means the increased amount of 
total proteins in the urine. Glomerular membrane 
damage and reduced protein absorption in the back 
tubules cause an increase of up to 300 mg in 24 h 
(Brown et al. 2001). Swelling is caused by the 
increased protein loss or the inadequate intake of 
fats and sugars. In the advanced stage of 
pregnancy, it may be caused by obstruction due to 
enlarged veins in the uterus (Felfernig-Boehm et 
al. 2000).  
Hyperuricemia is defined as the increased level of 
uric acid in the blood. If the level is higher than 
320 µM/L, it becomes one of the primary PE 
indicators. The most significant cause of 
hyperuricemia is the insufficient feedback 
resorption of uric acid in renal tubules (Cai et al. 
2009). HELLP syndrome differs from PE by 
hemolysis, the increased activity of liver enzymes 
and decreased level of platelets. HELLP is 
diagnosed in 20% of severe PE with the so-called 
thrombotic microangiopathy, which is defined as a 
syndrome involving the occurrence of clots in the 
veins, acute hemolytic anemia and 
thrombocytopenia (Felfernig-Boehm et al. 2000; 
Stara 2012). 
 
 
CLINICAL SCREENING FOR PRE-
ECLAMPSIA 
 
The PE markers include increased blood pressure, 
elevated or decreased protein in the urine, 
insufficient cerebral perfusion (headache, 
dizziness, tremor), nausea, vomiting, epigastric 
pain, distorted/double vision. Nowadays, the 
laboratory screening includes the monitoring of 
malondialdehyde levels, uric acid, fibronectin, 
human chorionic gonadotropin (hCG), increase in 
hemoglobin and hematocrit and the enzyme 
activity of selected enzymes (aspartate 
aminotransferase, alanine aminotransferase and 
lactate dehydrogenase). Malondialdehyde, which 
is a lipid peroxidation product, can be used as a 
new PE marker (Hajek 1999). Purine level is 
dependent on the influence of oxygen radicals. 
Although the released fibronectin from damaged 
vascular endothelial cells could theoretically 
contribute to PE prediction, this marker may easily 
provide false-positive results (Friedman and Schiff 
1995). 
 
 
ASSOCIATION OF OXIDATIVE STRESS 
AND PRE-ECLAMPSIA 
 
OS is an imbalance between the free radicals and 
ROS and their elimination by antioxidants. OS 
represents a disproportion between the oxidants 
and the antioxidants. This misbalance leads to cell 
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damage that may influence the entire body 
(Durackova 2010). ROS are described as the 
molecules of independent existence. Free radicals, 
with their unpaired electron, exhibit a high 
chemical reactivity towards other organic 
molecules. The main source of free radicals is the 
mitochondrial respiratory chain. It is known that 1- 
4% of oxygen is converted to superoxide and 
hydrogen peroxide during oxidative 
phosphorylation. Another source of free radicals is 
biotransformation process in the endoplasmic 
reticulum. The exogenous factors, which 
significantly increase the production of free 
radicals, are UV radiation, smoking, industrial 
pollution, pesticides, some pharmaceuticals and 
many organic solvents. ROS can cause 
intracellular reactions with lipids, DNA and 
proteins. These interactions can lead to the loss of 
cell permeability/genome stability and also other 
cellular functions (Cadenas and Sies 1998). PE 
causes hypoperfusion, placental ischemia and 
hypoxia and also reduces placental permeability so 
that reactive oxygen compounds are intensively 
produced. A reduced placenta can release various 
mediators such as the hCG hormone, cytokines, 
reactive oxygen and nitrogen species (nitrous 
oxide, hydrogen peroxide, superoxide anion). 
These mediators are detected when endothelial 
dysfunction occurs (Llurba et al. 2004). The 
throughput of reactive oxygen increases along PE 
developing during the pregnancy. This may lead to 
OS (Dennery 2010). The most important 
enzymatic oxidants are catalase, superoxide 
dismutase, glutathione-S-transferase, glutathione 
reductase and glutathione peroxidase (Kaur et al. 
2008). 
 
 
CONCLUSIONS 
 
Albeit the vast advances in research and 
knowledge of PE during recent times, the basic 
research is still lacking behind. This life-
threatening syndrome is the fatal culprit of 
perinatal morbidity/mortality, abortions or 
premature births. It is suggested that an inadequate 
trophoblast invasion leads to a reduced placental 
perfusion at the end of the first trimester, which is 
followed by endothelial dysfunction and clinical 
manifestation by the end of the second/during the 
third trimester. Despite the therapeutical progress, 
the diagnosis is still very complicated. Currently, 
 
the diagnosis of PE is based on clinical symptoms 
that are noticeable at the end of the second 
trimester. Therefore, great attention should be paid 
on the biochemical actions associated with the 
development of PE. The monitoring of 
biochemical markers could contribute to a better 
understanding and be helpful for early diagnosis. 
While the main causes of PE are still unknown, the 
current studies on biochemical processes 
associated with PE require much more attention 
and financial support. 
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